DALLAS and TORONTO, Feb. 29, 2024 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ('Perimeter' or the 'Company') – a commercial-stage medical technology company – announced results from a peer-reviewed retrospective study1 examining the integration of Wide Field Optical Coherence Tomography (WF-OCT) with Perimeter's proprietary and investigational 'ImgAssist' artificial intelligence technology, an AI-driven clinical decision support system created to enhance productivity and decision making in breast cancer surgery margin assessment..

达拉斯和多伦多，2024年2月29日/PRNewswire/-Perimeter Medical Imaging AI，Inc.（TSXV：粉红色）（OTC：PYNKF）（FSE：4PC）（“Perimeter”或“Company”）——一家商业阶段的医疗技术公司——宣布了一项同行评审的回顾性研究1的结果，该研究1检查了广域光学相干断层扫描（WF-OCT）的集成凭借Periment专有和研究性的“ImgAssist”人工智能技术，创建了一个人工智能驱动的临床决策支持系统，以提高乳腺癌手术边缘评估的生产力和决策能力。。

_____________________________1 Levy Y, Rempel D, Nguyen M, Yassine A, Sanati-Burns M, Salgia P, Lim B, Butler SL, Berkeley A, Bayram E. The Fusion of Wide Field Optical Coherence Tomography and AI: Advancing Breast Cancer Surgical Margin Visualization. Life. 2023; 13(12):2340. https://doi.org/10.3390/life13122340 .

_____________________________1 Levy Y，Rempel D，Nguyen M，Yassine A，Sanati Burns M，Salgia P，Lim B，Butler SL，Berkeley A，Bayram E.广域光学相干断层扫描与AI的融合：推进乳腺癌手术切缘可视化。生活。2023年；13（12）：2340。https://doi.org/10.3390/life13122340。

From a clinical perspective, the deep learning model showed high levels of sensitivity and specificity, accurately identifying 96.8% of pathology-positive margins. These results highlight the clinical viability of AI-enhanced margin visualization using WF-OCT in breast cancer surgery and its potential to decrease reoperation rates due to residual tumors..

从临床角度来看，深度学习模型显示出高水平的敏感性和特异性，可以准确识别96.8%的病理阳性边缘。这些结果突出了在乳腺癌手术中使用WF-OCT进行AI增强边缘可视化的临床可行性及其降低残留肿瘤再手术率的潜力。。

Adrian Mendes, Perimeter's Chief Executive Officer, stated, 'We have a training dataset of several million proprietary images of both cancerous and healthy tissue captured with our OCT imaging technology. Our world-class AI team has developed models tailored for real-time applications in healthcare settings and used our vast image library to train these models to achieve an industry-leading result.

Periment首席执行官阿德里安·门德斯（AdrianMendes）表示，“我们有一个训练数据集，其中包含数百万张用OCT成像技术拍摄的癌组织和健康组织的专有图像。我们世界一流的人工智能团队已经开发了针对医疗保健环境中实时应用而定制的模型，并使用我们庞大的图像库来训练这些模型，以实现业界领先的结果。

Perimeter's AI leadership represents a key value driver as we build a product pipeline that aims to improve surgical outcomes and broaden our addressable market through a variety of tissue types beyond breast.'.

Periment的人工智能领导地位代表了一个关键的价值驱动因素，因为我们建立了一条产品线，旨在通过乳房以外的各种组织类型来改善手术效果并拓宽我们的目标市场。”。

An ongoing, multi-center, randomized, two-arm, pivotal clinical trial – led by Principal Investigator, Dr. Alastair Thompson at Baylor College of Medicine – is evaluating the use of Perimeter B-Series OCT combined with its proprietary ImgAssist AI software during breast conservation surgery. Perimeter intends to conduct a planned interim analysis in the second quarter of 2024, with study completion anticipated by the end of 2024..

贝勒医学院（Baylor College of Medicine）首席研究员阿拉斯泰尔·汤普森（Alastair Thompson）博士领导的一项正在进行的多中心、随机、双臂、关键性临床试验正在评估在保乳手术中使用Periment B系列OCT及其专有的ImgAssist AI软件。Periment计划在2024年第二季度进行中期分析，预计2024年底完成研究。。

About Perimeter Medical Imaging AI, Inc.Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V: PINK) (OTC: PYNKF) (FSE: 4PC) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need.

关于Periment Medical Imaging AI，Inc.总部位于加拿大多伦多和德克萨斯州达拉斯，Periment Medical Imaging AI（TSX-V：粉红色）（OTC:PYNKF）（FSE:4PC）是一家医疗技术公司，旨在通过超高分辨率，实时，先进的成像工具来改造癌症手术，以解决高度未满足的医疗需求。

Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas.

我们的FDA认证的周长S系列OCT系统可在美国各地使用，可在细胞水平上实时显示切除组织的横截面。被指定为ImgAssist AI的研究周边B系列OCT的突破性设备代表了我们的下一代人工智能技术，该技术目前正在关键的临床试验中进行评估，并得到了德克萨斯州癌症预防和研究所授予的高达740万美元的资助。

The company's ticker symbol 'PINK' is a reference to the pink ribbons used during Breast Cancer Awareness Month..

该公司的股票代码“粉红色”是指在乳腺癌宣传月期间使用的粉红色缎带。。

Perimeter B-Series OCT is limited by U.S. law to investigational use and not available for sale in the United States.

Permiture B系列OCT受美国法律限制仅用于研究用途，不可在美国销售。

Perimeter S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by the U.S. FDA specifically for use in breast tissue, breast cancer, other types of cancer, margin evaluation, and reducing re-excision rates. The safety and effectiveness of these uses has not been established.

Periment S系列OCT在一般适应症下具有510（k）的清除率，并且尚未由美国FDA专门评估用于乳腺组织，乳腺癌，其他类型的癌症，边缘评估和降低再切除率。这些用途的安全性和有效性尚未确定。

For more information, please visit www.perimetermed.com/disclosures..

有关更多信息，请访问www.perimetermed.com/disclosures。。

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

TSX风险交易所及其监管服务提供商（该术语在TSX风险交易所的政策中定义）均不对本版本的充分性或准确性承担责任。

Forward-Looking StatementsThis news release contains statements that constitute 'forward-looking information' within the meaning of applicable Canadian securities legislation. In this news release, words such as 'may,' 'would,' 'could,' 'will,' 'likely,' 'believe,' 'expect,' 'anticipate,' 'intend,' 'plan,' 'estimate,' and similar words and the negative form thereof are used to identify forward-looking statements.

前瞻性声明本新闻稿包含的声明构成适用加拿大证券立法含义内的“前瞻性信息”。在本新闻稿中，诸如“可能”、“会”、“可能”、“会”、“可能”、“相信”、“期望”、“预期”、“打算”、“计划”、“估计”等词语以及类似词语及其否定形式被用来识别前瞻性陈述。

Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, plans and objectives of, or involving, Perimeter.

前瞻性信息可能与管理层的未来前景和预期事件或结果有关，可能包括有关未来财务状况、业务战略和战略目标、竞争条件、研发活动、预计成本和资本支出、研究和临床测试结果、计划和目标的声明或信息，或涉及周界。

Without limitation, statements regarding the potential benefits of Perimeter's work and technology and planned timing for Perimeter's interim analysis and the completion thereof, are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved.

不限于此，关于Periment工作和技术的潜在益处以及Periment中期分析的计划时间和完成时间的声明都是前瞻性信息。前瞻性陈述不应被视为对未来业绩或结果的保证，也不一定是对是否取得任何特定结果、何时取得任何特定结果的准确指示。

No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control.

不能保证前瞻性信息预期的任何事件将发生或发生。前瞻性信息基于当时可用的信息和/或管理层对未来事件的诚信信念，并受到已知或未知风险、不确定性、假设和其他不可预测因素的影响，其中许多因素超出了Periment的控制范围。

Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject.

这种前瞻性陈述反映了Periment对未来事件的当前观点，但本质上是主题。

SOURCE Perimeter Medical Imaging, Inc.

SOURCE Permiture Medical Imaging公司。